Corvus Pharmaceuticals Announces Publication In Science Signaling Demonstrating ITK Inhibition By Soquelitinib Induces Anti-Inflammatory Treg Cells; Study Highlights Potential For Treating Inflammatory Autoimmune And Allergic Diseases

7/25/24 8:35:13 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $CRVS alert in real time by email

Get the next $CRVS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CRVS

Date	Price Target	Rating	Analyst
8/18/2023	$7.00	Outperform	Oppenheimer
12/3/2021	$5.00 → $8.00	Overweight	Cantor Fitzgerald
12/1/2021	$8.00	Buy	Jefferies
8/3/2021	$4.00 → $3.50	Neutral	Mizuho
7/16/2021	$9.50 → $6.00	Buy	HC Wainwright & Co.

More analyst ratings

$CRVS
Press Releases

Fastest customizable press release news feed in the world

Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis
Adds to growing body of evidence supporting the potential of ITK inhibition as a novel therapeutic for the treatment of a wide range of immune diseases Data will be presented in a poster at ACR Convergence 2024, the annual meeting of the American College of Rheumatology BURLINGAME, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced new preclinical data highlighting the potential of soquelitinib, the Company's lead ITK inhibitor program, to prevent lung damage, inflammation and pulmonary hypertension caused by systemic sclerosis. "We continue to build evidence that selective ITK inhibition can
11/14/24 10:01:00 AM ET
$CRVS
Biotechnology: Pharmaceutical Preparations
Health Care
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results
Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Enrolling Patients in Second Dosing Cohort Interim Data from Atopic Dermatitis Trial Expected to be Announced December 2024 Registration Phase 3 Clinical Trial of Soquelitinib in Peripheral T Cell Lymphoma (PTCL) Enrolling with Multiple Clinical Sites Open Conference call today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the third quarter ended September 30, 2024. "
11/12/24 4:01:00 PM ET
$CRVS
Biotechnology: Pharmaceutical Preparations
Health Care
Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer
BURLINGAME, Calif., Nov. 09, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced new data highlighting the potential of ciforadenant, the Company's adenosine A2A receptor antagonist, to overcome resistance to anti-PD1 immunotherapy in the treatment of metastatic castration resistant prostate cancer (mCRPC). The data were presented today in an oral session at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting by Aram Lyu, Ph.D., a postdoctoral fellow at Fred Hutch Cancer Center, University of California, San Francisco and Parker Scholar at the Parker Institute for Cancer Immunotherapy. Dr. Lyu'
11/9/24 1:40:00 PM ET
$CRVS
Biotechnology: Pharmaceutical Preparations
Health Care

$CRVS
Financials

Live finance-specific insights

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024
BURLINGAME, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on November 12, 2024 at 4:30 pm ET (1:30 pm PT) to provide a business update and report third quarter 2024 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus' website for 90 days.
11/5/24 4:02:00 PM ET
$CRVS
Biotechnology: Pharmaceutical Preparations
Health Care
Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2024 Financial Results on August 6, 2024
BURLINGAME, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on August 6, 2024 at 4:30 pm ET (1:30 pm PT) to provide a business update and report second quarter 2024 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus' website for 90 days. Abou
7/31/24 8:30:00 AM ET
$CRVS
Biotechnology: Pharmaceutical Preparations
Health Care
Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024
BURLINGAME, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on May 6, 2024 at 4:30 pm ET (1:30 pm PT) to provide a business update and report first quarter 2024 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus' website for 90 days. About Cor
5/2/24 4:02:00 PM ET
$CRVS
Biotechnology: Pharmaceutical Preparations
Health Care

Corvus Pharmaceuticals Announces Publication In Science Signaling Demonstrating ITK Inhibition By Soquelitinib Induces Anti-Inflammatory Treg Cells; Study Highlights Potential For Treating Inflammatory Autoimmune And Allergic Diseases

Chat with this insight

Recent Analyst Ratings for $CRVS

$CRVS Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Corvus Pharmaceuticals Inc.

SEC Form SC 13G/A filed by Corvus Pharmaceuticals Inc. (Amendment)

SEC Form SC 13G filed by Corvus Pharmaceuticals Inc.

$CRVS SEC Filings

SEC Form 10-Q filed by Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Corvus Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

$CRVS Press Releases

Fastest customizable press release news feed in the world

Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results

Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer

$CRVS Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Grais Linda

SEC Form 4 filed by Director Clark Ian T

SEC Form 4 filed by Director Morrison Scott W

$CRVS Market Insights

Live Market Insights

Corvus Pharmaceuticals Announces Publication In Science Signaling Demonstrating ITK Inhibition By Soquelitinib Induces Anti-Inflammatory Treg Cells; Study Highlights Potential For Treating Inflammatory Autoimmune And Allergic Diseases

Corvus Pharmaceuticals shares are trading lower after the company reported Q1 financial results.

Oppenheimer Maintains Outperform on Corvus Pharma, Raises Price Target to $8

$CRVS Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

$CRVS Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Jones William Benton bought $34,624 worth of shares (20,000 units at $1.73), increasing direct ownership by 15% to 153,773 units (SEC Form 4)

Miller Richard A Md bought $1,000,000 worth of shares (577,634 units at $1.73) (SEC Form 4)

Oppenheimer initiated coverage on Corvus Pharmaceuticals with a new price target

Cantor Fitzgerald reiterated coverage on Corvus Pharmaceuticals with a new price target

Jefferies resumed coverage on Corvus Pharmaceuticals with a new price target

$CRVS Financials

Live finance-specific insights

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2024 Financial Results on August 6, 2024

Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024

$CRVS Leadership Updates

Live Leadership Updates

Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer

Corvus Pharmaceuticals Appoints Dr. James Rosenbaum Senior Vice President of Research

Recent Analyst Ratings for
$CRVS

$CRVS
Large Ownership Changes

$CRVS
SEC Filings

$CRVS
Press Releases

$CRVS
Insider Trading

$CRVS
Market Insights

$CRVS
Insider Purchases

$CRVS
Analyst Ratings

$CRVS
Financials

$CRVS
Leadership Updates